Three independent discounted-cash-flow-style models value Janux Therapeutics, Inc. Common Stock every trading day. 0 of 3 currently price JANX above its market price.
| Free Cash Flow model | $-73.41 |
| Excess Profit model | $-31.27 |
| Residual Earnings model | $-3.58 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | -11.6% |
| Net debt / EBITDA | — |
| Gross margin | +100.0% |
| Revenue CAGR | +5.1% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -15.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open JANX in StockKitty